Rifapex, a New Antituberculosis Agent
Abstract
Сlinісо-roentgenologlc and bacteriologic efficacy and safety of rifapex (rifapentin) were investigated in the complex therapy of 90 patients with newly recorded drug-susceptible tuberculosis. Pifapex was shown to be effective in the treatment of the patients during the acute phase of the disease, during the treatment completeness and during the short preoperative period.
About the Authors
G. B. Sokolova
I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of Tuberculosis
Russian Federation
Russian Federation
V. A. Krasnov
I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of Tuberculosis
Russian Federation
Russian Federation
T. A. Reikhrud
I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of Tuberculosis
Russian Federation
Russian Federation
A. A. Tsybanev
I.M. Sechenov Moscow Medical Academy, Moscow; Novosibirsk Research Institute of Tuberculosis
Russian Federation
Russian Federation
References
1. Vemon A., Burman W., Benatoret D. et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847
2. American Thoracic Society, CDC. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149: 1359-1374
Review
For citations:
Sokolova G.B., Krasnov V.A., Reikhrud T.A., Tsybanev A.A. Rifapex, a New Antituberculosis Agent. Antibiot Khimioter = Antibiotics and Chemotherapy. 2009;54(1-2):38-41. (In Russ.)
Views:
480
Email this article 